Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Haining Wang; Ye Liu; Qing Tian; Jin Yang; Ran Lu; Siyan Zhan; Jari Haukka; Tianpei Hong

doi:10.1111/dom.13177

Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Haining Wang, Ye Liu, Qing Tian, Jin Yang, Ran Lu, Siyan Zhan, Jari Haukka, Tianpei Hong

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	Diabetes, obesity and metabolism
Vuosikerta	20
Numero	4
Sivut	910-920
Sivumäärä	11
ISSN	1462-8902
DOI - pysyväislinkit	https://doi.org/10.1111/dom.13177
Tila	Julkaistu - huhtikuuta 2018
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3121 Sisätaudit
3142 Kansanterveystiede, ympäristö ja työterveys

Pääsy asiakirjaan

10.1111/dom.13177

Siteeraa tätä

@article{a6c70db34ce4400d862edc2d31c3dbc8,

title = "Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials",

keywords = "dipeptidyl peptidase-4 inhibitors, GLP-1 analogue, incretins, meta-analysis, type 2 diabetes, DIPEPTIDYL PEPTIDASE-4 INHIBITOR, PRANDIAL INSULIN LISPRO, ADD-ON THERAPY, DOUBLE-BLIND, INITIAL COMBINATION, NON-INFERIORITY, CARDIOVASCULAR OUTCOMES, RECEPTOR ACTIVATION, CLINICAL-TRIAL, OPEN-LABEL, 3121 Internal medicine, 3142 Public health care science, environmental and occupational health",

author = "Haining Wang and Ye Liu and Qing Tian and Jin Yang and Ran Lu and Siyan Zhan and Jari Haukka and Tianpei Hong",

year = "2018",

month = apr,

doi = "10.1111/dom.13177",

language = "English",

volume = "20",

pages = "910--920",

journal = "Diabetes, obesity and metabolism",

issn = "1462-8902",

publisher = "Wiley",

number = "4",

}

Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes : A meta-analysis of randomized controlled trials. / Wang, Haining; Liu, Ye; Tian, Qing; Yang, Jin; Lu, Ran; Zhan, Siyan; Haukka, Jari; Hong, Tianpei.

julkaisussa: Diabetes, obesity and metabolism, Vuosikerta 20, Nro 4, 04.2018, s. 910-920.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes

T2 - A meta-analysis of randomized controlled trials

AU - Wang, Haining

AU - Liu, Ye

AU - Tian, Qing

AU - Yang, Jin

AU - Lu, Ran

AU - Zhan, Siyan

AU - Haukka, Jari

AU - Hong, Tianpei

PY - 2018/4

Y1 - 2018/4

KW - dipeptidyl peptidase-4 inhibitors

KW - GLP-1 analogue

KW - incretins

KW - meta-analysis

KW - type 2 diabetes

KW - DIPEPTIDYL PEPTIDASE-4 INHIBITOR

KW - PRANDIAL INSULIN LISPRO

KW - ADD-ON THERAPY

KW - DOUBLE-BLIND

KW - INITIAL COMBINATION

KW - NON-INFERIORITY

KW - CARDIOVASCULAR OUTCOMES

KW - RECEPTOR ACTIVATION

KW - CLINICAL-TRIAL

KW - OPEN-LABEL

KW - 3121 Internal medicine

KW - 3142 Public health care science, environmental and occupational health

U2 - 10.1111/dom.13177

DO - 10.1111/dom.13177

M3 - Article

VL - 20

SP - 910

EP - 920

JO - Diabetes, obesity and metabolism

JF - Diabetes, obesity and metabolism

SN - 1462-8902

IS - 4

ER -